Scarica l'app Stockscreener
30.35
3.94%
1.15
Dopo l'orario di chiusura:
29.75
-0.60
-1.98%
Precedente Chiudi:
$29.20
Aprire:
$29.45
Volume 24 ore:
507.96K
Relative Volume:
2.05
Capitalizzazione di mercato:
$3.71B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+10.89%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$28.39
$31.51
Intervallo di 1 settimana:
$26.68
$31.51
Portata 52W:
$24.51
$34.47
Parabilis Medicines Inc Stock (PBLS) Company Profile
Nome
Parabilis Medicines Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare PBLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
30.35 | 3.57B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Parabilis Medicines Inc Borsa (PBLS) Ultime notizie
Leerink Partners Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $40 - Moomoo
Leerink initiates Parabilis Medicines stock with Outperform rating By Investing.com - Investing.com South Africa
The biggest biotech funding rounds in June 2026 - Labiotech.eu
PBLS Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway - TipRanks
Michael Schmidt Initiates Buy on Parabilis Medicines, Citing Helicon Platform and Zolucatetide as Key Value Drivers with $40 Price Target - TipRanks
BofA Securities initiates Parabilis Medicines stock coverage with buy rating - Investing.com
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Guggenheim initiates Parabilis Medicines stock with buy rating - Investing.com
PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Large VC financings improve in H1 2026 - BioWorld News
Nasdaq Delivers the Strongest First Half in U.S. Exchange History as Public Markets Momentum Builds - Moomoo
Mass. biotech IPO proceeds near $3.2B, close in on pandemic-era record pace - The Business Journals
Insider Stock Purchases: June 29, 2026 - Quiver Quantitative
[Form 4] Parabilis Medicines, Inc. Insider Trading Activity - Stock Titan
Parabilis Medicines (PBLS) holder reports 527,070-share Series F position - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
PBLS|Parabilis Medicines Ord Shs|Price:28.800|Chg%:2.44 - TradingKey
Price to earnings forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Price to book forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
PBLS: Parabilis Medicines, Inc.12 Month EPS - Zacks Investment Research
Price to sales forward of Parabilis Medicines, Inc. – BOATS:PBLS - TradingView
Parabilis Medicines (PBLS) Insider Trading Activity 2026 - MarketBeat
Enterprise value to EBIT forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Parabilis Medicines (PBLS) Stock Trends and Sentiment 2026 - MarketBeat
Parabilis Medicines, Inc. (PBLS) Book Value (Per Share) - Zacks Investment Research
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Total operating expenses of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? - The Globe and Mail
PBLSParabilis Medicines Inc Forecast, Target Price - Finviz
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
RA Capital Management Discloses Investment at Parabilis Medicines with 23.8% Stake - TradingView
[SCHEDULE 13D] Parabilis Medicines, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
PBLS SEC FilingsPARABILIS MEDICINES INC 10-K, 10-Q, 8-K Forms - Stock Titan
PBLS Technical Analysis & Stock Price Forecast - Intellectia AI
PBLS PE Ratio & Valuation, Is PBLS Overvalued - Intellectia AI
PBLS | Parabilis Medicines, Inc. Common Institutional Ownership - Quiver Quantitative
Apothecary Capital, tied to Parabilis (PBLS) director, buys 17,500 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Parabilis Medicines stock jumps on insider buying activity By Investing.com - Investing.com Nigeria
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines stock jumps on insider buying activity - Investing.com
PBLS | Parabilis Medicines, Inc. Common Insider Trading - Quiver Quantitative
RA Capital funds lift Parabilis Medicines (PBLS) common equity exposure - Stock Titan
Parabilis Medicines (PBLS) director converts preferred stock into common around IPO - Stock Titan
Parabilis (PBLS) director-linked LLC makes open-market buy of 12,500 shares - Stock Titan
Parabilis Medicines (PBLS) director converts Series F preferred into common in IPO - Stock Titan
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline - Yahoo Finance
PBLS : Parabilis Medicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Parabilis Medicines Inc Azioni (PBLS) Dati Finanziari
Non sono disponibili dati finanziari per Parabilis Medicines Inc (PBLS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Parabilis Medicines Inc Azioni (PBLS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SEBULSKY ALAN | Director |
Jun 15 '26 |
Buy |
26.49 |
9,065 |
240,135 |
30,000 |
| SEBULSKY ALAN | Director |
Jun 12 '26 |
Buy |
27.67 |
8,435 |
233,393 |
20,935 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
20.00 |
21,188,750 |
423,775,000 |
26,285,093 |
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):